Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin® Program / Grant Supports Personalized Anti-cancer Approach on Path to Clinic
Freising, Germany (ots) - Pieris AG announced today the receipt of a EUR 1 million grant to support the development of the company's proprietary PRS-110 compound targeting c-Met, a cellular receptor that plays a key role in cancer cell growth and metastasis. The goal of the funded research will be to delineate a ...
mehr